Cardiovascular Safety of Testosterone-Replacement Therapy.
A Michael LincoffShalender BhasinPanagiotis FlevarisLisa M MitchellShehzad BasariaWilliam E BodenGlenn R CunninghamChristopher B GrangerMohit KheraIan M ThompsonQiuqing WangKathy WolskiDeborah DaveyVidyasagar KalahastiNader KhanMichael G MillerMichael C SnabesAnna ChanElena DubcencoXue LiTingting YiBidan HuangKarol M PencinaThomas G TravisonSteven E Nissennull nullPublished in: The New England journal of medicine (2023)
In men with hypogonadism and preexisting or a high risk of cardiovascular disease, testosterone-replacement therapy was noninferior to placebo with respect to the incidence of major adverse cardiac events. (Funded by AbbVie and others; TRAVERSE ClinicalTrials.gov number, NCT03518034.).